Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Hematopoietic and Lymphatic System Neoplasm 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteonecrosis 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Hypertension 1Head and Neck Neoplasms 1Depressive Disorder 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

Cisplatin 130Cetuximab 79Radiotherapy 76Docetaxel 58Carboplatin 46pembrolizumab 45Paclitaxel 44Fluorouracil 42Radiotherapy, Intensity-Modulated 35Drug Therapy 17Radiation 14Nivolumab 14Gefitinib 14Gemcitabine 13Surgical Procedures, Operative 12Oxaliplatin 11Erlotinib Hydrochloride 11Pemetrexed 10Celecoxib 10Capecitabine 10Bevacizumab 10130-nm albumin-bound paclitaxel 10tislelizumab 9Filgrastim 9Amifostine 9Albumin-Bound Paclitaxel 9durvalumab 7atezolizumab 7Chemoradiotherapy 7toripalimab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Head and Neck Neoplasms × Interviews as Topic × Clear all
NCT06997068 2026-05-11

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

Mayo Clinic

Phase 2 Recruiting
25 enrolled
Head & Neck

Carcinoma, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡